See more : Trencor Limited (TRE.JO) Income Statement Analysis – Financial Results
Complete financial analysis of ZyVersa Therapeutics, Inc. (ZVSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZyVersa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Consorcio ARA, S. A. B. de C. V. (CNRFF) Income Statement Analysis – Financial Results
- Esker SA (ALESK.PA) Income Statement Analysis – Financial Results
- Arkle Resources PLC (ARK.L) Income Statement Analysis – Financial Results
- AbCellera Biologics Inc. (ABCL) Income Statement Analysis – Financial Results
- PT Wulandari Bangun Laksana Tbk (BSBK.JK) Income Statement Analysis – Financial Results
ZyVersa Therapeutics, Inc. (ZVSA)
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.40K | 10.40K | 10.40K | 10.40K |
| Gross Profit | -10.40K | -10.40K | -10.40K | -10.40K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.21M | 5.41M | 2.12M | 6.47M |
| General & Administrative | 11.21B | 7.61M | 5.58M | 5.36M |
| Selling & Marketing | -11.20B | 0.00 | 0.00 | 0.00 |
| SG&A | 11.20M | 7.61M | 5.58M | 5.36M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.41M | 13.01M | 7.70M | 11.83M |
| Cost & Expenses | 14.42M | 13.01M | 7.70M | 11.83M |
| Interest Income | 0.00 | 427.54 | 821.37 | 516.45 |
| Interest Expense | -457.00K | 427.54K | 821.37K | 516.45K |
| Depreciation & Amortization | 10.40K | 10.40K | 10.40K | 10.40K |
| EBITDA | -107.74M | -11.67M | -7.25M | -12.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.42M | -13.01M | -7.70M | -11.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -93.33M | -2.37M | -379.79K | -850.11K |
| Income Before Tax | -107.75M | -14.05M | -8.08M | -12.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.46M | 745.05M | 821.37K | 516.45K |
| Net Income | -98.30M | -759.10M | -8.91M | -13.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.09K | -930.25 | -173.66 | -272.45 |
| EPS Diluted | -1.09K | -930.25 | -173.66 | -272.45 |
| Weighted Avg Shares Out | 97.50K | 25.95K | 46.55K | 46.55K |
| Weighted Avg Shares Out (Dil) | 97.50K | 25.95K | 46.55K | 46.55K |
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
WESTON, Fla., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen...
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100's Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
WESTON, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of a paper in the peer-reviewed Journal...
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100's Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
WESTON, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of a paper in the peer-reviewed journal,...
ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results
Key Highlights : Advanced clinical development initiatives for Cholesterol Efflux Mediator™ VAR 200, with planned initiation of a Phase 2a clinical trial in diabetic kidney disease (DKD) in the first quarter of 2024 Granted a European patent covering Phase 2a-ready...
Top 5 Health Care Stocks That Could Blast Off In August
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
WESTON, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases with high unmet needs, announced today...
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
WESTON, Fla., July 17, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed journal,...
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.
WESTON, Fla., July 14, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen...
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
WESTON, Fla., July 10, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed journal...
European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
WESTON, Fla., July 07, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that the European Patent Office granted a patent...
Source: https://incomestatements.info
Category: Stock Reports
What were ZyVersa’s Q3 2024 net losses?
Net losses were approximately $2.4 million for the three months ended September 30, 2024, with an improvement of approximately $0.5 million or 17.3% compared to a net loss of approximately $2.9 million for the three months ended September 30, 2023.